MICA and hyperthyroidism: Similar to Wang's study, our study provided strong evidence that the MICA‐STR polymorphism might be clinically useful as a pharmacogenetic predictor, and we propose that MICA*A5.1 carriers should be given cautiously treated with ATD for hyperthyroidism and monitored intensely.